Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02380677 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02380677: Clinical Trial Phase 1 study, sponsored by NewLink Genetics Corporation.
NCT02380677 is a Phase 1 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02380677, a Phase 1 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
A Phase 1/2a, open-label, dose-escalation study with enrollment in Phase 1 to continue until determination of the Maximum Tolerated Dose (MTD) /Recommended Phase 2a Dose (RP2D), and then enrollment into Phase 2a expansion cohorts will be initiated.
Primary Outcome
Determination of MTD is dependent upon number of dose limiting toxicities and significant adverse events observed.
Interventions
- DRUG CRLX301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-10-04 |
| Phase | Phase 1 |
Why NCT02380677 stopped before completion
NCT02380677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 1 intervention - of which CRLX301 is the first listed.
NCT02380677 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02380677 about?
NCT02380677 is a clinical study titled "Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors". A Phase 1/2a, open-label, dose-escalation study with enrollment in Phase 1 to continue until determination of the Maximum Tolerated Dose (MTD) /Recommended Phase 2a Dose (RP2D), and then enrollment into Phase 2a expansion cohorts will be initiated.
What is the current status of trial NCT02380677?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2015-04. Estimated completion is 2017-10-04.
What interventions are being tested in trial NCT02380677?
The interventions under investigation include: CRLX301 (DRUG).
Who is sponsoring clinical trial NCT02380677?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02380677's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia